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Systems: Scanning the Proteome
for Targets of Organic Small Molecules
enzymes or other protein targets in complex mixtures
based on their catalytic or ligand binding activities [9–
16]. Clearly, the sequencing of the human genome and
the many recent technological advances have increased
the versatility, sophistication, and scale with which com-
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plex data sets can be generated, analyzed, and interpre-
ted—notwithstanding the many challenges still associ-The integration of technological advances in areas as
ated with managing the volume and quality of large datadiverse as chemical biology, proteomics, genomics,
sets.automation, and bioinformatics has led to the emer-
An integrative technology-driven approach, such asgence of novel screening paradigms for analyzing the
that seen in functional genomics and proteomics re-molecular basis of drug action. This review summa-
search, should also facilitate the development of sys-rizes recent advances in three-hybrid technologies
tems for more rapid and large-scale identification ofand their application to the characterization of small
small molecule ligand binding proteins. Traditionally, themolecule-protein interactions and proteome-wide
identification of receptors for small molecules has reliedidentification of drug receptors.
on in vitro biochemical methods, such as photocross-
linking, radiolabeled ligand binding, and affinity chroma-
Introduction tography. Affinity chromatography-based approaches
have improved significantly in recent years, aided by
A critical and difficult challenge in many areas of bio- technological advances in protein separation and analy-
medical research has been the identification and char- sis. However, these methods are still laborious and time
acterization of protein targets of organic small mole- consuming, interactions identified by such methods
cules. For instance, research pursuant to the “chemical may not be direct (proteins may be purified as compo-
genetics” paradigm utilizes small molecules as molecu- nents of protein complexes), and cloning of cDNAs en-
lar probes for a quantitative and temporal perturbation coding candidate targets is uncoupled from the target
of protein function [1, 2]. This approach emulates all the identification process. To circumvent these problems,
principles of genetics, but rather than relying on genetic several functional cloning methods have been devel-
mutations to dissect protein function, it uses small mole- oped in recent years. These include yeast three-hybrid
cules. Although this approach holds great promise for (Y3H) [17], drug-western [18], phage display cloning [19],
deciphering functions encoded by the human genome, and mRNA display cloning [20]. In all of these methods,
its current utility is limited by the difficult task of identi- the identification of ligand binding proteins is inherently
fying the intracellular target spectrum for any given small linked to the selection of cDNA sequences encoding
molecule probe. The identification of protein targets of such interactors. The Y3H system (as well as other three-
small molecules is of course also crucial in pharmaceuti- hybrid systems) distinguishes itself from these other
cal research, where a lack of a thorough understanding methods in that interactions between small molecules
of mechanism of action may significantly limit the lead and proteins occur in living cells rather than in vitro.
optimization process and the development of therapeu- The development of three-hybrid systems, such as
tics with optimal efficacy and safety profiles. Identifica- Y3H, has drawn from recent advances in (1) the design
tion of small molecule targets could also lead to novel and application of synthetic small molecules that can
therapeutic applications for a drug or drug candidate. interact with two proteins simultaneously, also known
In the wake of the sequencing of the human genome, as chemical inducers of dimerization (CIDs), or chemical
as well as various other genomes, the past few years “dimerizers”, and (2) two-hybrid protein-protein interac-
have seen a significant increase in the development of tion screening technologies (such as the yeast two-
systematic approaches designed to elucidate the role of hybrid system, or Y2H). This review summarizes the
small molecules in perturbing cellular processes. These evolution of and recent advances in three-hybrid tech-
approaches have variously been labeled with the terms nologies for the analysis of small molecule-protein inter-
chemical biology, chemical genomics, and chemical actions as well as current and foreseeable applications
proteomics, and integrate various technological ad- in chemical biology and drug discovery.
vances in areas of assay design, chemistry, functional
genomics, proteomics, automation engineering, and bio-
informatics with access to an increasing number of Chemical Dimerizers and Cellular Signaling
cloned genes and their associated sequences. For in- Studies on the mechanisms of action of the immunosup-
stance, genome-wide gene expression profiling, and, to pressive macrocyclic lactone lactams FK506 and rapa-
an increasing extent, protein expression profiling are mycin paved the way for the subsequent development
being used to profile the effect of a small molecule on of small molecule three-hybrid systems. FK506 and ra-
signaling pathways [3–8], and a variety of chemically pamycin are examples of small molecules, which have
reactive probes are being used to profile and identify become termed chemical “dimerizers,” meaning that by
binding to two proteins simultaneously, they crosslink
these proteins and promote the formation of a ternary*Correspondence: nikolai.kley@gpc-biotech.com
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Figure 1. Chemical Inducers of Dimerization
(CIDs) and Cell Signaling
Examples of uses of homo- and heterodimer-
izing CIDs.
(A) Induction of gene expression by rapa-
mycin [25, 26, 30].
(B) Induction of gene expression by synthetic
FK506-based dimerizers (FK1012 and AP1510)
[30, 32].
(C) Recruitment of Fas tail to membrane-
anchored FKBP and activation of apoptotic
signal by the FKCsA (FK506-Cyclosporin A)
heterodimer [33]. FRB, FKBP12-rapamycin
binding domain of FRAP; CyP, cyclophilin;
AD, transcription activation domain; DBD,
DNA binding domain; RE, DNA response el-
ement.
complex. Important early findings concerning the mech- A [33], were used to homodimerize and heterodimerize
various hybrid proteins (Figure 1). A further refinementanism of action of FK506 and rapamycin were that their
biological effects required as an obligatory but not suffi- in “dimerizer technology” was the generation of analogs
of rapamycin [34] and FK506 [35] that recognized andcient step the formation of a complex with the immu-
nophilin FKBP12 (FK506 binding protein). Thus, FK506 bound only to appropriately mutated forms of FRAP or
FKBP12, thereby also reducing their cytotoxicity. Chem-binds to FKBP12; this binary complex is able to bind
calcineurin, a Ca2/calmodulin-dependent protein phos- ical homo- and heterodimerizers have been used to con-
trol a variety of signal transduction events in cellsphatase, thereby inhibiting its function [21]. The inactiva-
tion of calcineurin results in impaired signaling of the engineered to express chimeric proteins encoding ap-
propriate ligand binding domains and signaling do-T cell antigen receptor (TCR) and subsequent immuno-
suppression. Similarly, rapamycin binds to FKBP12, and mains, such as induction of membrane recruitment and
activation of cytosolic signaling proteins [36–39], cross-the resultant complex is able to bind FRAP (FKBP12-
rapamycin-associated protein, also named RAFT1, linking of plasma membrane receptors and activation
of receptor signaling [31, 40–44], induction of transloca-RAPT1, or TOR) [22–25]. The inhibition of FRAP in T
lymphocytes blocks interleukin 2 receptor signaling, tion of proteins into the nucleus [33], and activation of
gene expression by recruitment of transcriptional activa-which is thought to be the basis for the immunosuppres-
sive actions of rapamycin. Another example of an immu- tors to specific genes [29, 30, 32, 33], both exogenous
transgenes and endogenous genes [45]. In this manner,nosuppressant that acts in this manner is cyclosporin
A, which forms a complex with cyclophilin, which then cellular processes such as programmed cell death and
cellular proliferation [33–35, 42, 46] or the expressionbinds calcineurin [21].
The understanding of these mechanisms led to the and secretion of proteins with therapeutic potential were
placed under the control of chemical dimerizers [26, 29,use of rapamycin and FK506, and various analogs
thereof, to effect at will the crosslinking (“dimerization”) 30]. More recently, small molecule ligands have been
employed to assemble as well as disassemble com-of hybrid proteins that have been designed to contain
the appropriate binding sites for these small molecules, plexes of FKBP12, and to create cells that can secrete
biologically active hormones under the control of de-thereby controlling intracellular signaling events that are
naturally or otherwise regulated by protein-protein inter- signer FK506 analogs [47, 48]. The broad uses of CIDs
may eventually constitute the basis for drugs that controlactions [1]. Thus, rapamycin was used to dimerize hybrid
proteins containing FKBP12 and FRAP rapamycin bind- fate or function of genetically modified cells in gene
therapy treatments [29, 30].ing domains [26–30] (Figure 1). Synthetic dimeric versions
of FK506, such as bivalent FK506-FK506 (appropriately While rapamycin and its analogs (also known as “rapa-
logs”) have been widely used as chemical dimerizers,called FK1012) [31], FK1510 [32], or FK506-cyclosporin
Review
601
it was the synthesis and use of the synthetic hybrid ceptor (GR) fused to a DNA binding domain (LexA), and
the other being FKBP12 fused to a transcriptional activa-ligand/dimerizer FK1012 (dimeric FK506) [31] that
marked the beginning of three-hybrid systems for either tion domain of the bacterial protein B42 [17]. The use
of mutant forms of the GR, which displayed higher affin-homo- or heterodimerization of chimeric proteins (i.e.,
the crosslinking of two hybrid proteins, same or differ- ity for dexamethasone (nanomolar) than wild-type GR,
was necessary for detection of the interaction. Theseent, by a hybrid/bivalent synthetic small molecule).
FK1012 was used to induce aggregation of a T lympho- findings suggest that affinities in at least the nanomolar
range are most likely required for successful display ofcyte receptor fused to FKBP12 [31]. Alternatively,
FK506-cyclosporin A was used to heterodimerize hybrid a synthetic hybrid ligand (e.g., DEX-FK506) by the DBD-
fusion protein (e.g., LexA-GR). Importantly, Licitra andproteins [33]. Other dimeric analogs of FK506 that have
been used in different settings include FK1510 [32] and Liu showed that the DEX-FK506 heterodimer could be
used to identify FKBP12 in a cDNA library screen, dem-AP1903 [35]. The latter recognizes specifically a mutant
form of FKBP12. None of these studies, however, incor- onstrating that the Y3H system could, in principle, be
used to screen complex cDNA libraries to identify drugporated a small molecule test compound as a moiety
of a hybrid ligand for the purpose of de novo identifica- receptors.
Since the first report on Y3H, various types of syn-tion of proteins that would bind such a test compound.
Such an approach would require a robust screening thetic ligands have been deployed for use in Y3H, using
small molecules with known and high affinity for particu-system that would allow for expression of complex
cDNA libraries and straightforward selection of produc- lar receptor proteins (DEX, FK506, and methotrexate,
MTX). A recent report described the use of a DEX-MTXtive interaction events. The Y2H system [49, 50] pre-
sented such an opportunity. hybrid ligand in the identification of dihydrofolate reduc-
tase (DHFR), the known receptor for MTX, in a cDNAThe Y2H system has been a most notable and widely
used technology for the detection and identification of library screen [59]. Analogously, Cornish and colleagues
demonstrated the use of MTX-DEX dimerizers in whichinteractions of hybrid proteins in living cells on a large
scale [16]. Since its inception by Fields and colleagues, MTX was used as the anchor moiety of the dimerizer
[60–62]. MTX has a high affinity for its target, DHFR.the basic concept of Y2H has been applied and modified
to create many approaches for measuring association Binding of MTX to DHFR follows a two-step mechanism,
with isomerization to the second, high-affinity complexor dissociation of macromolecules, including (1) RNA-
protein interactions [51], (2) protein-peptide interactions being the rate-determining step. Interestingly, although
the inhibition constants (Ki) of MTX for both the E. coli[52], (3) protein-antibody interactions [53], (4) hormone-
regulated association of protein-protein interactions [54, DHFR (eDHFR) and murine DHFR (mDHFR) are indistin-
guishable, 1–20 pM depending on experimental condi-55], (5) the screening for small molecules that disrupt
or interfere with protein-protein interaction [56–58], (6) tions [63–67], the eDHFR monomeric protein has been
shown to be significantly more effective in displayingprotein dimerization in response to the natural product
rapamycin [25], and (7) protein crosslinking (dimeriza- MTX-DEX for binding to the glucocorticoid receptor [61].
It appears that the initial complex for mDHFR is 100tion) by synthetic chemical homo- or heterodimerizers
(i.e., the Y3H system) [17]. Features of Y3H and other times less stable than for eDHFR and is characterized
by a rapid off-rate (koff). Whether this is the basis for thepotential three-hybrid systems are described in more
detail below. observed differences remains unclear. Whether MTX-
based hybrid ligands would be suitable for the de novo
identification of small molecule binding proteins using
Yeast Three-Hybrid Systems: Identification cDNA library screens also remained unclear. This was,
of Small Molecule Protein Targets however, demonstrated in a very recent study designed
The basic elements of the Y3H system are schematically to explore the utility of Y3H in screening for targets of
described in Figure 2. It is based on the use of three small molecule kinase inhibitors [78]. The results of this
hybrid molecules: a hybrid protein that contains a DNA study showed that a LexA(DBD)-DHFR fusion protein
binding domain (DBD) fused to a first small molecule could be used in conjunction with MTX-based hybrid
ligand binding domain (LBD), a hybrid protein that con- ligands to identify known and novel targets of purine
tains a transcriptional activation domain (AD) fused to analogs. This study also shed light on how a Y3H system
a second ligand binding domain, and a bivalent hybrid may perform in satisfying numerous criteria essential
molecule. The hybrid small molecule consists of an “an- for an effective screening platform. For example, it was
chor moiety” with known binding affinity for the LBD of shown that library screens can be performed at high
the DBD-fusion protein, a “test compound” moiety, for complexity and redundancy, the emergence of false
which binding proteins are to be identified, and a linker, positives can be controlled for and easily suppressed
which covalently links the two distinct small molecule using appropriate genetic counterscreens and a combi-
moieties to form a bivalent hybrid ligand. A productive nation of diverse hybrid ligands, interactions can be
interaction of the test compound with the ligand binding detected with a high degree of specificity, and interac-
domain of the AD-fusion protein results in recruitment tions of components with known affinities in the micro-
of this protein to DNA, an event that results in activation molar range or higher can be detected with such a sys-
of the expression of a downstream reporter gene. tem. Furthermore, it became apparent that the Y3H
The first report on Y3H described the use of a dexa- system could be used to characterize the interaction of
methasone (DEX)-FK506 heterodimer to crosslink two ATP-competitive active site kinase inhibitors with both
serine/threonine kinases (including cyclin-dependent ki-chimeric proteins, one displaying the glucocorticoid re-
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Figure 2. The Yeast Three-Hybrid (Y3H)
System
Y3H is a three-hybrid system that exploits
the modular characteristics of transcriptional
activators [17]. Two chimeric proteins are ex-
pressed within the same yeast cell. One chi-
mera is composed of a DNA binding domain
(DBD, e.g., derived from bacterial LexA or
yeast GAL4 transcriptions factors) and a li-
gand binding domain with known character-
istics (LBD, e.g., DHFR). The second chimera
is composed of a transcriptional activation
domain (AD, e.g., derived from the bacterial
protein B42 or yeast GAL4) fused to a poly-
peptide (protein Y) of interest. The small mol-
ecule heterodimer is composed of an “anchor
moiety” capable of binding to the LBD portion
of the DBD-LBD protein (e.g., MTX, which
binds DHFR) and a linker which tethers it to
a test compound of interest. Interaction of
the test compound with protein Y promotes
a ligand-dependent dimerization of the chi-
meric proteins, resulting in the reconstitution
of a macromolecular complex with transcrip-
tion-activating function. Recruitment of the
complex to specific DNA binding sites (re-
sponse elements, RE) upstream of a promoter
region results in activation of a downstream reporter gene. Thus, induction of reporter expression reflects ligand-dependent dimerization of
the chimeric proteins. In a yeast three-hybrid system, a reporter gene may, for instance, encode an auxotrophic marker (e.g., HIS3, induction
of which enables yeast growth in the absence of histidine in the growth medium), an enzymatic marker (e.g., LacZ, detected in colorimetric
assays), or a fluorescent marker (e.g., GFP). Random screening for small molecule targets can be performed on a proteome-wide scale by
transforming a suitable yeast strain with an AD-fusion protein-encoding cDNA library.
nases) and tyrosine kinases (including receptor tyrosine to solid-phase surfaces for protein purification [68].
Thus, integrating PEG linkers in the synthesis of a CIDkinases). Kinases constitute an important class of thera-
peutic targets, and the availability of a screening system can yield derivatives of test compounds for parallel and
straightforward use in standard biochemical assays.for profiling the target space (kinase and nonkinase)
for such inhibitors should prove useful across different PEG linkers of variable lengths have been used in the
synthesis of heterodimeric ligands [78], which have inareas of biomedical research. The findings that interac-
tions with affinities in a range that is of pharmacological general shown good solubility properties and, surpris-
ingly, were able to penetrate yeast cells well. The ratio-interest/relevance can be detected with Y3H also sug-
gest that Y3H may be used in the context of a broader nale for this is not well understood, but the findings hold
promise for the use of Y3H with a broad range of smallrange of types of synthetic small molecules.
As discussed above, a chemical dimerizer is com- molecules. At GPC Biotech, we have analyzed over 50
MTX-PEG-based heterodimeric molecules to date andposed of essentially three parts, with a linker connecting
an anchor moiety (e.g., MTX) and a test compound of have not seen any significant drop-out due to lack of
compound uptake (although variability in uptake is ob-interest. Choice of linker type may be governed by a
number of considerations: linker length should be easily served). Figure 3 depicts a general strategy that has
been pursued in the synthesis of MTX-based heterodi-variable, as this may affect the performance of the hybrid
ligand. Coupling of the linker to the test compound mers with PEG linkers. Similar strategies should be pos-
sible with other types of anchor molecules, such asshould be feasible using different chemistries such as
to facilitate the synthesis of a broad range of CIDs with FK506 and its analogs.
different linkages. The number of synthesis steps in gen-
erating a CID should be minimal with an overall accept- Toward High-Throughput Y3H Screening Systems
Over the past decade, the scientific community hasable yield. Finally, linkers should ideally improve solubil-
ity and cell permeability of a hybrid ligand. The use of made broad use of the Y2H system. In recent years,
the emergence of large-scale genomics and proteomicsstraight-chain aliphatic linkers of variable length has
been reported for the synthesis of MTX-DEX CIDs [61]. approaches has changed ways in which certain technol-
ogies are developed and deployed, including Y2H. Thus,A three-methylene linker did not result in a functional
CID. However, five-, eight- and ten-methylene linkers Y2H has been used in large-scale screening formats to
map protein-protein interactions and potential signalingperformed nearly equally well. Thus, a minimal linker
length appears necessary for these CIDs to work effec- networks at the proteome level, as exemplified by stud-
ies using model systems such as yeast, C. elegans, andtively. The synthesis required nine steps with an overall
yield of 2%–5%. Alternatively, a recent study made use D. melanogaster [16]. Similarly, the use of yeast in Y3H
should also facilitate larger-scale screening for smallof polyethyleneglycol (PEG) linkers [78]. PEG linkers
have been used previously in coupling small molecules molecule-protein interactions.
Review
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Figure 3. A Strategy for the Synthesis of Chemical Dimerizers
A general strategy for the synthesis of methotrexate-based chemical dimerizers (CIDs), which has been applied to the synthesis of heterodimers
with polyethylene glycol (PEG) linkers [78], is shown. En route to synthesis of the dimer, a PEGylated derivative of the test compound is
generated, which can be used in diverse biochemical assays requiring coupling of the test compound to solid phase. A diversity of chemical
reactions could be applied when using different functional groups for coupling reactions (e.g., amide, amine, ether linkages).
Important benefits that derive from using yeast as a of interest, once established, is a permanent resource
for screening, with each experiment increasing the infor-host system for analyzing macromolecular interactions
extend beyond its easy manipulation, both genetically mation content about ligand binding properties of that
particular expressed protein(s). Since probing for ligandand from an experimental perspective, and the reason-
able costs of high complexity screening. Yeast can also binding in a Y3H system does not require a priori knowl-
edge of the biochemical activity of the protein or proteinsbe manipulated easily using modern robotics and auto-
mation technology. Yeast cells may be easily arrayed of interest, no individual assay system is required for
each protein. Hence, three-hybrid gene family screeningand cultured on agar plates or membranes. Multiple
replicas of yeast arrays can be generated in this manner, may include members whose biological functions are
unknown. An example of an array analysis would beeach of which may be subjected simultaneously to dif-
ferent selection criteria (e.g., growth conditions) or inter- the use of comprehensive “kinase arrays” in selectivity
profiling of kinase inhibitors.rogated with a diverse set of hybrid ligands (see Figure
4). Besides improving data output quality, array analyses Figure 4 depicts how two-hybrid and three-hybrid
based technologies, in conjunction with other techno-have greatly increased the flexibility with which yeast
systems may be deployed. In the case of Y3H, the imple- logical and experimental approaches to small molecule
mode-of-action studies (e.g., gene expression), couldmentation of yeast cell arrays was found to be extremely
useful for generating high quality data on small mole- lead to a more comprehensive picture of molecular
events underlying drug effects. Integration of diversecule-protein interactions, whether used to “validate” in-
teractions identified in cDNA library screens or in direct technological approaches with mode-of-action studies
will remain an ongoing challenge but will benefit thescreening of selected genes/proteins [78]. Not surpris-
ingly, array-based analysis also seems to be more sensi- drug discovery process.
tive than complex cDNA library screening. In an array
screening format, each potential small molecule-protein Toward Mammalian Three-Hybrid Systems
As compared to Y2H, the Y3H system greatly benefitsinteraction is tested individually; hence, no competitive
growth selection is taking place, and weak interactions from the fact that the DBD-fusion protein for a given
system (e.g., LexA-DHFR) remains invariant and thatcan be detected more easily. Another important benefit
of array-based analyses is that defined ORF (open read- multiple control CIDs can be used simultaneously to
rapidly sort for bona fide interaction events. The Y3Hing frame) collections, e.g., a gene family of interest,
may be rapidly screened (within days) with a set of small system, however, does share some limitations inherent
to the Y2H system. Thus, it is limited to the analysis ofmolecules of interest. Furthermore, each recombinant
yeast cell that expresses a selected gene/hybrid protein proteins that can be expressed and translocate into the
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Figure 4. Y3H and Y2H Array Screening in Drug Mode-of-Action Studies
Screening scenarios that utilize the arraying of recombinant yeast cells for the analysis of either small molecule-protein (Y3H) or protein-
protein interactions (Y2H) are shown. The Y3H workflow highlights robotic replica arraying of recombinant yeast cells in 96-well type array
formats (i.e., 96 proteins may be assayed simultaneously) for parallel interrogation with compounds. Recombinant cells may be generated
with a set of genes of interest (e.g., gene families or genes previously identified in random cDNA library screens). Composite interaction
images can be generated rapidly and hierarchical clustering analyses performed to reveal spectra of proteins that may interact with a given
small molecule or spectra of small molecules that a given protein interacts with. Targets identified using Y3H may subsequently be subjected
to Y2H studies for mapping of signaling pathways. Robotic arraying of recombinant yeast cells can be used to generate complex arrays for
the analysis of reporter gene expression (e.g., LacZ, as shown) in response to two-hybrid protein-protein interactions. Replica arrays can also
be used to interrogate such arrays under different selection criteria (genetic counter screens) and testing for the dependence of an interaction
event on the presence of both hybrid proteins (e.g., panel A, growth of arrayed yeast cells [cells are spotted in duplicate]; panel B, activation
of LacZ reporter when both hybrid proteins are present; panel C, no LacZ reporter activation under conditions that deselect for presence of
one hybrid protein; panel D, no LacZ reporter activation when the other hybrid protein is deselected; panel E, replica filters can be generated
for hybridization with DNA probes). This type of array analysis increases Y2H data output quality. The integration of data sets resulting from
use of Y2H, Y3H, and other experimental approaches (e.g., gene expression studies) can lead to the construction of putative signaling network
maps that can be visualized using bioinformatic visualization tools. Visualization of composite data sets may drive the generation of new
hypotheses and experimental strategies for more comprehensive mode-of-action studies, leading to a better understanding of the molecular
basis of drug action.
nucleus of yeast cells. Additionally, it is not suitable for limits the use of Y3H in “competition” experiments com-
paring the interaction of a parent test molecule with athe analysis of full-length membrane proteins (although
it can work with domains of membrane proteins) or small hybrid ligand incorporating that small molecule with a
target protein. Genetically modified yeast strains withmolecule-protein interactions that require accessory
proteins or certain posttranslational modifications of the improved permeability to small molecules have recently
been used in screening for compounds that disrupt Y2Htarget proteins that are not compensated for by endoge-
nous yeast proteins. Yeast cells are also generally less protein-protein interactions [58]. Analogously, modified
yeast strains could potentially be used in some Y3Hpermeable to small molecules than mammalian cells,
with the previously noted interesting exception, it applications. Alternatively, one could use a different host
system with better permeability to small molecules inseems, of MTX-heterodimers. The variable and generally
less favorable uptake of small molecules by yeast cells particular mammalian cells. Access to a mammalian sys-
Review
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Figure 5. Three-Hybrid Applications in Drug
Discovery
Three-hybrid systems can, in principle, be
used to identify protein targets of small mole-
cules or, alternatively, novel small molecules
for a specific protein(s) of interest and, as a
consequence, have the potential of impacting
the drug discovery process at multiple
stages. A broader understanding of the mo-
lecular basis of drug action should help guide
medicinal chemistry efforts in lead optimiza-
tion, reveal targets that may be associated
with adverse side effects, identify targets for
known leads/drugs that could point toward
novel therapeutic uses, and provide informa-
tion that may lead to reactivation of failed
drug discovery programs (drug rescue).
tem(s) could conceivably also provide an additional and the detection of some interactions that require post-
translational modifications of the protein target as wellpowerful platform for interaction screening.
Driven by the limitations of the Y2H system, various as be suitable for rapid testing of interactions between
parent test compounds and protein targets (“competi-complementary two-hybrid systems have been devel-
oped over the past years, all of which could, in principle, tion experiments”).
be adapted for use in a three-hybrid fashion in mamma-
lian cells. Indeed, making various two-hybrid systems Three-Hybrid System Screening Modalities
The yeast three-hybrid system can be used in differentapplicable for cDNA library screening purposes should
be easier for three-hybrid applications, given the afore- ways to study the interaction of small molecules with
target proteins. As discussed earlier, it may be employedmentioned fact that one of the two chimeric proteins
remains invariant (e.g., the DBD-LBD chimera in Y3H). in the screening of cDNA libraries for targets of small
molecules or in a more focused analysis of defined tar-Two-hybrid systems for mammalian cells include (1) the
ubiquitin-split-protein-sensor (USPS) technology [69, get classes. Both approaches are useful in determining
the target space of small molecules and in performing70]; (2) two-component protein fragment complementa-
tion assays (PCAs), e.g., systems based on reconstitu- more comprehensive structure-activity relationship (SAR)
studies. Alternatively, as previously suggested [17], Y3Htion of split-DHFR [71] or split--lactamase [72, 73]
(these have already been shown to support dimerizer- could be used to rapidly test for mutations in proteins
that either positively or negatively affect binding to ainduced interactions); and (3) interaction technologies
based on resonance energy transfer between reporter small molecule. An analogous approach has been used
to identify FKBP or FRAP mutants that bind specificproteins with fluorescent or bioluminescent properties,
i.e., FRET (fluorescence resonance energy transfer) and analogs of FK506 and rapamycin [34, 35]. Similarly, such
an approach could be used to identify drug-resistantBRET (bioluminescence resonance energy transfer). It is
important to note, however, that although these systems mutant target proteins that could conceivably retain bio-
logical activity and be used to explore the role of a targethave been used to detect defined protein-protein inter-
actions in mammalian cells, none of these has yet been in mediating a pharmacological effect of a compound
of interest. Alternatively, the Y3H system could be usedutilized successfully in complex cDNA library screens
for the discovery of novel interactions. The reason for to screen for compounds that interfere with binding of
a particular hybrid ligand to a selected target. The designthis may be that the detection of interactions in these
systems is subject to more stringent steric and spatial of a reverse-Y3H system, analogous to the reverse-Y2H
system [56], could be useful for such a purpose, although,requirements. In contrast, MAPPIT, a recently reported
two-hybrid-based technology established for mamma- as indicated earlier, a mammalian three-hybrid system
would be more desirable. Finally, focused small mole-lian cells, has been used successfully in library screens
[74]. MAPPIT distinguishes itself from the other afore- cule libraries, synthesized on scaffolds of anchor moie-
ties (e.g., MTX) could be used to identify small moleculesmentioned systems in that it exhibits properties of a
“protein recruitment” system, in which a signaling pro- with interesting interaction profiles across a specific
gene family. Verdine and colleagues have recently re-tein-protein complex is activated upon recruitment to a
“docking station” (i.e., an intracellular receptor domain). ported the synthesis of AP1867 (a FK506 analog) based
combinatorial libraries [75]. It is conceivable that suchIn that regard, MAPPIT shares some similarity to Y2H, in
which an AD-fusion protein is recruited to DNA through types of compound libraries could be used to screen
for phenotypic effects of small molecules in cells, fol-protein complex formation. Thus, MAPPIT could be a
suitable system for the development of a mammalian lowed by direct identification of targets mediating such
effects using a three-hybrid system.three-hybrid screening system. It should also support
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Y.D., et al. (2000). Functional discovery via a compendium ofRecently, Cornish and colleagues reported yet an-
expression profiles. Cell 102, 109–126.other functional cloning application of a three-hybrid
5. Waring, J.F., and Ulrich, R.G. (2000). The impact of genomics-system [76]. In this case, the three-hybrid system was
based technologies on drug safety evaluation. Annu. Rev. Phar-
used to assay for an enzymatic activity of a protein macol. Toxicol. 40, 335–352.
expressed in yeast cells that could cleave the linker 6. Ulrich, R., and Friend, S.H. (2002). Toxicogenomics and drug
discovery: will new technologies help us produce better drugs?moiety of a defined dimerizer (MTX-linker-dexametha-
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